Navigation Links
Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today the results from its Special Meeting of Shareholders held on Tuesday, March 24, 2009.

At the meeting, shareholders approved the proposal to increase the number of shares of authorized stock (including an increase in the number of shares of authorized common stock), the proposal to increase the number of shares available for issuance under its 2007 Equity Incentive Plan and the proposal to increase the number of shares available for issuance under its 2007 Employee Purchase Plan. The proposal to allow the Board of Directors to implement a reverse split if and when the Board deems such action appropriate was not approved by the shareholders.

"We appreciate the support of our shareholders as it is important both from an operational and a strategic perspective as we move our products and programs toward approval," said James A. Bianco, M.D., CEO of CTI. "With excellent phase III data for pixantrone for aggressive relapsed non-Hodgkin's lymphoma we plan to complete the New Drug Application (NDA) submission in the second quarter of 2009 and we believe that this product would truly make a significant impact on this difficult to treat patient population. While we now have approval for additional authorized shares, we intend to continue to pursue product partnerships to generate operating capital."

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular, including, without limitation, our ability to submit an NDA in the first half of 2009 for pixantrone and gain approval in 2009, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, our ability to identify and negotiate product partnerships, our ability to raise additional capital to fund our continued operations, determinations by regulatory, patent and administrative governmental authorities including but not limited to decisions regarding the review and approval of applications submitted to the FDA or the EMEA, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Cell Therapeutics, Inc.
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    Lindsey Jesch
    T : 206.272.4347
    F : 206.272.4434

    Investors Contact:
    Cell Therapeutics, Inc.
    Ed Bell
    T: 206.272.4345
    F: 206.272.4434

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
2. Oxygen Biotherapeutics, Inc. Expands Board of Directors
3. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
6. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
7. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
8. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
9. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... BRUSSELS , November 25, 2015 ... la première fois les différences entre les souches ... de celles des êtres humains . Ces ... comprendre et envisager la prise en charge efficace de ... ent diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
Breaking Biology Technology:
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/19/2015)... Calif. , Nov. 19, 2015  Based on ... Frost & Sullivan recognizes BIO-key with the 2015 Global ... Each year, Frost & Sullivan presents this award to ... line catering to the needs of the market it ... product line meets and expands on customer base demands, ...
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 companies ... dominated by a few companies, according to Kalorama Information. These ... 51% of the market share of the 6.1 billion-dollar ... The World Market for Molecular Diagnostic s .    ... market is still controlled by one company and only ...
Breaking Biology News(10 mins):